CMS Acting Administrator notes the agency has been discussing approaches to a Part D payment experiment with manufacturers interested in ‘defining’ such a program.
The Centers for Medicare and Medicaid Services is considering payment demonstrations in Medicare Part D and has been talking to biopharma manufacturers about outcomes-based risk sharing contracting, CMS Acting Administrator Andy Slavitt told the BioPharma Congress Nov. 3.
“Manufactures have approached us with ideas … probably five or six times,” to ask whether the agency would be interested in certain alternative payment demonstrations, he said
EU-level joint clinical assessments conducted under the Health Technology Assessment Regulation need to be more flexible when it comes to evidence requirements, according to experts speaking at a gene and cell therapy conference.
During its first quarter earnings call, Moderna avoided criticizing vaccine policy changes, but de-emphasized its flu/COVID-19 vaccine for those under age 50 and prioritized cancer programs.
US HHS Advisor Calley Means said new pathways for root-cause treatments are part of the HHS Secretary Robert F. Kennedy Jr.’s vision for the FDA. But what most biopharma companies consider preventative medicines are not what he has in mind, nor does he seem to see those companies as part of the solution.
